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Summary
Maintaining homoeostatic host–microbe interactions is vital for host 
immune function. The gut microbiota shapes the host immune system and 
the immune system reciprocally shapes and modifies the gut microbiota. 
However, our understanding of how these microbes are tolerated and how 
individual, or communities of, gut microbes influence host function is lim-
ited. This review will focus on metabolites as key mediators of this complex 
host–microbe relationship. It will look at the central role of epithelial me-
tabolism in shaping the gut microbiota, how microbial metabolites influence 
the epithelium and the mucosal and peripheral immune system, and how 
the immune system shapes microbial composition and metabolism. Finally, 
this review will look at how metabolites are involved in cross-talk between 
different members of the microbiota and their role during infections.
Keywords: autoimmunity, dysbiosis, host-pathogen interactions, infection, 
inflammation, physiological hypoxia
Introduction
The intestinal tract is colonized by a plethora of microbes 
known collectively as the gut microbiota. From ants to 
humans, these gut microbes play important roles in main-
taining host physiology: from nutrient acquisition and 
synthesis, energy homoeostasis, maintenance of coloniza-
tion resistance and immune development and maintenance 
[1,2]. Dysbiosis, meaning a disruption in the normal 
microbiota, is associated with a plethora of immune, 
metabolic and even neurological diseases [3–6]. A com-
mon trait in dysbiosis is a shift from obligate anaerobes 
to facultative anaerobe or aerobic microorganisms [7,8]. 
Causes of dysbiosis include environmental factors such 
as antibiotic use and western-style high-fat diet [3], but 
host genetic factors that regulate gut epithelial function 
and oxygen metabolism, or disease states, may also underlie 
dysbiosis [3,7,8]. As such, it is often uncertain whether 
dysbiosis causes disease or is a result [9]. While the 
understanding of host–microbe interactions has advanced 
enormously over the past 20  years, there is still much 
more yet to be defined. With rapidly advancing multiomics 
technologies we are gaining insight into how metabolism, 
and metabolites, are key to supporting the host– 
microbe relationship.
Colonic epithelial metabolism shapes gut microbial 
composition and vice versa
The intestinal epithelium is at the interface of host and 
microbe interactions. Epithelial integrity is vitally important 
for maintaining host health, as loss of barrier integrity 
can lead to dissemination of intestinal bacteria, disruption 
of nutrient acquisition, water loss and activation of mucosal 
inflammation. Epithelial metabolism has been proposed 
to be central in establishing the hypoxic environment of 
the colon lumen that is critical to maintaining obligate 
anaerobic commensal/mutualistic microbes [7], but the 
main energy source of colonocytes is butyrate, a metabolic 
by-product of the gut microbiota, suggesting that micro-
biota presence is the first most important step for estab-
lishing the host–microbe interface. This cyclical relationship 
between host epithelial metabolism providing a niche for 
gut microbes and gut microbes providing an energy source 
for the epithelium, make it difficult to dissect the under-
pinning mechanisms at the basis of host–microbe 
homoeostasis.
Members of the healthy gut microbiota are important 
for the digestion of complex plant polysaccharides (fibre) 
from the diet by fermentation and as such, germ-free 
mice exhibit an enlarged caecum, due to the build-up of 
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undigested dietary fibre, and defects in energy har-
vest  –  particularly in colonocyte energy homoeostasis 
[10–17]. Fermentation of dietary fibre results in the pro-
duction of short chain fatty acid (SCFA), including acetate 
(C2), propionate (C3) and butyrate (C4). It has long been 
established that colonocytes preferentially utilize butyrate 
as an energy source, and doing so utilizes oxygen, with 
butyrate metabolism accounting for approximately 85% 
of oxygen consumption by colonocytes [17–21]. Germ-free 
mice exhibit decreased epithelial nicotinamide adenine 
dinucleotide hydrogen (NADH)/NAD+  and ATP levels, 
marked by decreased mRNA and protein expression of 
various genes involved in metabolism [17], which high-
lights the importance of the microbiota for epithelial 
metabolism. Host colonization starts from birth (the fetus 
is considered largely sterile) and during the first months 
and years microbes inhabiting the gut undergo successive 
waves of colonization. First, pioneering aerobic or faculta-
tive anaerobes dominate before obligate anaerobes assemble 
and diversity appears [22–24]. Experiments in germ-free 
mice indicate that obligate anaerobes cannot colonize the 
intestine without prior colonization with aerobic or fac-
ultative anaerobes [25], which suggests that these pioneers 
are involved in establishing a relationship with the host.
Several studies have begun to unravel the pathways 
involved in regulating colonic epithelial metabolism and 
the interplay between epithelium and gut microbiota. 
[7,17,21,26–28]. As colonic epithelial cells differentiate they 
acquire expression of peroxisome proliferator-activated 
receptor gamma  (PPARγ) [29], which activates fatty acid 
metabolism enabling mitochondrial β-oxidation and oxi-
dative phosphorylation with butyrate as the fuel source 
[17,27]. This utilizes large amounts of oxygen, causing 
very low levels of oxygen at the mucosal surface (<10 mm/
Hg = <1%) [30–32]. Limited oxygen diffusion from the 
mucosal tissue into the gut lumen makes the hypoxic 
environment suitable for harbouring obligate anaerobic 
microbes [7,27]. Obligate anaerobic microbes then pref-
erentially occupy this niche, preventing growth of faculta-
tive anaerobes [7]. A further layer of complexity is that 
butyrate itself activates PPARγ [33], making a closed 
circuit of mutual benefit, but also making it difficult to 
ascertain where the cycle initially starts (Fig. 1). As 
described above, obligate anaerobes cannot colonize a 
germ-free host without the prior colonization with an 
aerobic organism. This suggests that early microbial signals 
may be required to instigate the transcriptional network 
that activates PPARγ and subsequent high levels of oxygen 
utilization.
Given that enterocytes at the tip of the colonic crypt 
exist in a virtually hypoxic environment, they must need 
to adapt to these conditions to prevent cell death. It has 
been demonstrated that butyrate metabolism and 
subsequent oxygen utilization is sufficient to stabilize 
hypoxia-inducible factor (HIF) in the colonic epithelium 
[21]. HIF stabilization is important for activating a cel-
lular signature of physiological hypoxia, inducing numerous 
targets that are involved in maintaining barrier function 
[34]. For example, HIF binds to intestinal trefoil factor 
(ITF), an important mediator of barrier function [26]. 
Thus, enterocytes are adapted to function and maintain 
barrier integrity within this physiological hypoxic 
environment.
Together, these studies suggest that establishment of 
the transcriptional networks that enable high oxygen 
consumption by colonocytes and ability to function in 
physiological hypoxia is critical to establishing the host–
microbe relationship, and that early pioneering gut 
microbes may be required to initiate such transcriptional 
networks. Perturbations in epithelial metabolism (genetic, 
disease, damage, other) or perturbations in the gut 
microbiota (antibiotics, diet, infection, inflammation, 
other) could disrupt this host–microbe metabolic inter-
dependence. Future studies looking to unravel the com-
plex interplay between host epithelium, microbiota and 
establishment of this physiological hypoxia may need 
to look at the events during early host colonization in 
order to understand more clearly what the first signals 
are that activate this cyclic interaction between host 
and microbe. These pathways are less studied in the 
small intestine, but physiological hypoxia is also appar-
ent in the small intestine [35]. Future studies might 
also look into the effect of fluctuations in blood flow 
and thereby oxygen abundance, which occurs following 
feeding. Just a fraction of mucosal capillaries are used 
under fasting conditions, whereas in the fed state intes-
tinal blood flow can increase up to 200% [35]. An 
interesting question is whether an overfed state, such 
as that which typically occurs in developed countries 
where food is abundant, could lead to increased oxy-
genation of the intestinal villus and lumen leading to 
altered microbiomes overserved in western cultures, 
contributing to dysbiosis and disease development or 
amplification.
Commensal metabolites and their effects on the 
intestinal epithelium
The gut microbiota have enormous effects on the host, 
not only through the presence of microbe-associated 
molecular patterns (MAMPs), but also through metabo-
lites they generate. As discussed above, fermentation of 
dietary fibre results in SCFA production, and butyrate 
is particularly important for intestinal epithelial homoeo-
stasis. Butyrate also has further effects on epithelial cells 
through inhibition of histone deacetylases (HDACs) [36] 
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and butyrate, as well as the other SCFAs, acetate and 
propionate, also have roles in regulating immune func-
tions, which will be discussed later. Aside from SCFA, 
many other metabolites have been found to directly 
influence the intestinal epithelium, which will be discussed 
more here.
Lactic-acid producing bacteria (LAB) are known to 
exert a range of beneficial effects on gut homoeostasis 
and mucosal and systemic immunity [37–40], but the 
mechanisms of action are not well characterized. A 
recent study has shown direct effects of lactate produced 
by LAB on Paneth cells and submucosal stromal cells 
via G-protein coupled receptor 81 (GPR81) [41], a 
lactate-specific receptor [42–44]. Production of Wnt 
ligands by Paneth cells is important for the maintenance 
of stem cells [45]. Intestinal stromal cells and subepi-
thelial mesenchymal cells also express Wnt ligands, and 
have also been shown to support intestinal stem cells 
[46,47]. Lee et al. [41] found that GPR81 is expressed 
on Paneth and submucosal stromal cells, and that 
engagement of lactate induced Wnt ligands resulting 
in differentiation of intestinal stem cells [41]. 
Functionally, lactate provided by LAB, or supplementa-
tion in the drinking water, improved intestinal repair 
following radiation and chemotherapy-induced damage 
when given prophylactically [41]. LAB deficient in lactate 
dehydrogenase, and thereby lactate production, could 
not exert this beneficial effect, and Gpr81–/– mice have 
defective intestinal regeneration due to impaired Wnt3 
activation [41].
Fig. 1. Metabolic interplay between host and gut microbes. Colonic epithelial metabolism of butyrate is central to establishing the host–microbe 
relationship. Butyrate is a by-product of fermentation of dietary and host-derived complex carbohydrates. Certain species of the gut microbiota are 
responsible for short-chain fatty acid (SCFA) production (acetate, propionate and butyrate); these are critical members of the community and 
dysbiosis is often characterized by their loss. Enterocytes at the tip of the villi are main users of butyrate; they express Peroxisome proliferator-
activated receptor gamma (PPARy) (which can be induced by butyrate) which activates β-oxidation and oxidative phosphorylation. High amounts of 
oxygen are consumed in this process, making the top of the intestinal crypts physiologically hypoxic. This ensures limited oxygen diffusion into the 
gut lumen, thereby creating an environment suitable for obligate anaerobes. Hypoxia induces hypoxia-inducible factor (HIF), which activates a 
transcriptional network important for maintaining epithelial integrity. SCFA also have a variety of effects on the mucosal and peripheral immune 
systems, largely acting in a regulatory capacity, limiting inflammatory responses. They also regulate immunoglobulin (Ig)A production via retinoic 
acid production by dendritic cells, which in turn also modulates microbiota composition.
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Amino acid metabolism is regulated by the gut microbiota, 
which affects the amount and type of amino acids available 
to the host [48–50]. Tryptophan is an essential amino acid 
important for the generation of a range of bioactive mol-
ecules, including serotonin and melatonin [51]. The host 
utilizes the majority of diet-derived tryptophan, but the gut 
microbiota also metabolize a portion resulting in indole-
containing molecules [52,53]. Several of these are aryl hydro-
carbon receptor ligands and regulate mucosal immunity, 
which will be discussed in later sections, and is also discussed 
in detail in a review by Roager and Licht [54].
One commensal, Clostridium sporogenes, metabolizes all 
three aromatic amino acids (AAA), including tryptophan. 
Analysis of the metabolic pathway involved revealed that 
there are 12 resulting metabolites, nine of which accu-
mulate in host serum, including indolepropionic acid (IPA) 
[52]. IPA was found to be important for maintaining 
barrier integrity, and lack of IPA and the other AAA 
metabolites increased intestinal permeability [52,55]. IPA 
was shown to bind epithelial pregnane X receptor (PXR), 
inducing down-regulation of tumour necrosis factor 
(TNF)-α and up-regulation of junctional protein-encoding 
mRNAs [55]. Systemic immunity was affected by dimin-
ished IPA production, with increased percentage of neu-
trophils and CD8 T cells and increased anti-C. sporogenes 
immunoglobulin (Ig)A [52]. This work demonstrates that 
active maintenance of the intestinal barrier, as instructed 
by microbial metabolites, is critical for maintaining the 
host tolerance of the gut microbiota.
Tryptamine is a tryptophan-derived monoamine, which 
has structural similarity to 5-hydroxytryptamine (serotonin) 
and is produced by gut microbes. Bhattarai et al. [56] 
observed that microbial-derived tryptamine activates the 
5-HT4 receptor (5-HT4R) on the intestinal epithelium, 
increasing colonic secretion and decreasing the time taken 
for gastric emptying (transit time). Thus, this microbial 
derivative of tryptophan may have important roles in regu-
lating responses to infection which rely on intestinal secre-
tions to flush out the pathogen [56]. Tryptamine, or bacteria 
engineered to produce tryptamine, may also represent a 
novel treatment for diseases distinguished by slow transit 
time, such as irritable bowel syndrome (IBS). 
Pharmacological agonists of the 5-HT4R have been trialled 
for IBS; however, significant side effects can occur due to 
activation of this receptor on other cell types, such as heart 
muscle cells. Thus, specific delivery of a 5-HT4R ligand to 
the gut would be a desirable treatment option [56].
Effect of commensal metabolites on host immune 
function
Microbial diversity has been identified as an important 
factor in mediating immune development and maintenance 
of homoeostasis. Many inflammatory and autoimmune 
diseases are associated with dysbiosis, but whether dys-
biosis is the cause or consequence of these diseases is 
difficult to dissect. In any case, dysbiosis at least acts to 
amplify inflammation [9]. Sequencing of human micro-
biomes has revealed a wide variation in species composi-
tion, thus making it difficult to ascribe beneficial, or 
detrimental, effects to specific species. Instead, it is emerging 
that common functional activities and metabolites are 
conserved between individuals. Thus, it appears that func-
tional metabolic niche fulfilment is more important than 
specific individual species within the microbiota [9,57,58]. 
Numerous metabolites present in the circulation are 
dependent on the presence of gut microbiota [53]; thus, 
it is not surprising that the microbiota can exert effects 
on the host beyond the gut, including effects on host 
metabolism, the endocrine system, brain and peripheral 
immune and inflammatory responses [3,5,6,58–60]. This 
review will focus on a few examples of microbial metabo-
lites affecting host mucosal and peripheral immune 
responses.
Dysbiosis is commonly associated with a shift towards 
aerobes and facultative anaerobes and decreased levels of 
SCFAs [4,7,61,62]. SCFAs, acetate, propionate and butyrate, 
were found to bind G-protein coupled receptors GPR41 
and 43 with varying affinity [63,64]. In a landmark paper, 
we described a diet–microbiota–host immune axis where 
microbial metabolism of dietary fibre resulted in SCFA 
production, and acetate in particular activated GPR43 on 
innate immune cells, including eosinophils and neutrophils 
[65]. Acetate ligation of GPR43 on neutrophils affected 
chemotaxis, reactive oxygen species (ROS) and phagocytic 
activity. In the absence of microbiota, colitis and arthritis 
was exacerbated, and this could be rescued by addition 
of acetate in the drinking water [65]. Mice lacking Gpr43 
also exhibited exacerbated colitis, arthritis and allergic 
airway responses, which could not be rescued by addition 
of acetate to the drinking water [65]. Numerous other 
effects of SCFA, whether receptor-dependent or -inde-
pendent have now been reported [66–69].
Antibiotic treatment-induced dysbiosis can have wide-
reaching effects, for example on inflammation, infection 
and responses to vaccination [70–72]. Antibiotics have been 
shown to affect SCFA-producing bacteria causing a decrease 
in SCFA abundance [73,74]. In a recent study, macrophage 
dysfunction was noted following antibiotic-induced dys-
biosis causing aberrant activation of T helper type 1 (Th1) 
cells, leaving mice susceptible to Th17 and Th2-type infec-
tions [75]. The authors demonstrated that SCFA were 
reduced following antibiotics, and that supplementing 
butyrate could restore macrophage hyporesponsiveness to 
microbial ligands and prevent Th1 over-activation [75], 
thus showing a wider effect of antibiotics on the host 
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beyond microbial composition and effects on colonization 
resistance. This observation is likely to also be applicable 
to conditions where SCFA are known to have peripheral 
effects and also suggest that antibiotic treatment would 
affect other microbial-derived metabolites.
Acetate and butyrate have also been found to affect 
IgA responses. In two separate studies, acetate was found 
to affect CD103+  dendritic cell retinol dehydrogenase 
activity resulting in increased retinoic acid (RA) produc-
tion, which increased intestinal IgA production [66,76]. 
Tan et al. additionally showed enhanced T follicular helper 
cell function supporting mucosal germinal centre reactions 
[66]. This enhanced mucosal IgA production was important 
for controlling food allergy responses, with zero fibre 
feeding, or knock-outs of Gpr43 or Gpr109A (butyrate 
receptor), being more susceptible to food allergy [66].
Within the mucosal tissue, SCFAs, butyrate in particular, 
is important for maintaining immune homoeostasis 
through induction of regulatory T cells (Tregs) [77,78]. 
Butyrate-stimulated Treg expansion in the lamina propria 
and bone marrow has been shown to promote interaction 
between bone marrow Tregs and CD8 T cells, increasing 
production of Wnt10b by CD8 T cells, which has effects 
on stromal cells and osteoclasts promoting bone forma-
tion [79]. Supplementation of Lactobacillus rhamnosus GG 
(LGG) had previously been shown to affect bone forma-
tion, but the mechanisms had not been described. In this 
study, they confirm that LGG increases bone mass via 
increased circulation of butyrate. Interestingly, LGG itself 
is not responsible for butyrate production, but promotes 
other bacterial species that produce butyrate [79], again 
highlighting the complex interplay between different micro-
bial communities and how a particular species may not 
be the key dominant factor, but rather that fulfilment of 
a metabolic niche is important for maintaining 
homoeostasis.
The maternal gut microbial composition and products, 
particularly SCFA, have been shown to affect immune 
development in offspring [80,81]. In one study, high-fibre 
feeding or supplementation with acetate reduced suscep-
tibility to allergic airway disease (AAD) in mice, and 
furthermore could supress AAD development in the off-
spring of mice fed on a high-fibre/acetate diet during 
pregnancy [80]. This, they showed, had an effect on Treg 
expression of forkhead box protein 3 (FoxP3) and block-
ing Tregs ablated the beneficial effects of acetate on AAD 
development [80]. Nakajima et al. [82] have shown that 
microbial-derived butyrate affected thymic expression of 
Aire, which is known to be important for Treg selection 
in the thymus. In further studies, they demonstrated that 
maternal delivery of butyrate increased thymic expression 
of Gpr41 and Aire and increased thymic and peripheral 
Treg numbers [81]. This study did not determine if the 
altered Treg number had any effect on peripheral immune 
responses but, coupled with the other studies described 
above, the data would suggest that SCFA can affect Treg 
development via a multitude of mechanisms [77–81].
While many studies have found effects of SCFA, other 
microbial-derived metabolites are also being discovered 
to affect immune responses. Morita et al. [83] found that 
GPR31 expression on CX3CR1+ intestinal dendritic cells 
senses bacterial-produced lactate and pyruvate and medi-
ates dendrite extension and luminal sampling. 
Supplementation of lactate or pyruvate enhanced uptake 
and immune responses to S. typhimurium infection, which 
was not afforded in Gpr31–/– mice. Engagement of lactate 
with its other receptor, Gpr81, on intestinal dendritic cells 
and macrophages was also shown to reduce colitis by 
suppressing cytokine production and Th1/Th17 cell dif-
ferentiation [84], but whether this was due to gut microbe-
generated lactate in particular was not addressed.
Effect of the host immune system on composition of 
the gut microbiota
IgA plays a critical role in controlling the composition 
and diversity of the intestinal microbiota [85,86]. The 
importance of maintaining bacterial composition by IgA 
is highlighted by the fact that people with selective IgA 
deficiency have a higher predisposition to autoimmune 
diseases [9,87]. IgA not only limits enteric pathogens 
[88,89], but also actively promotes beneficial microbes. 
For example, IgA coating enhances Bacteroides fragilis 
habitation of the mucous and mediates intimate interac-
tions with the intestinal epithelium [90].
A recent study showed further importance of IgA coat-
ing of a strain of Bacteroidetes, which was important for 
modulating interphylum bacterial interactions and co-
operation via shared metabolism [91]. Aiming to test 
whether glycan–glycan interactions between IgA, bacteria 
and mucous are important for modulating gut microbiota, 
Nakajima et al. [91] developed a highly glycosylated anti-
ovalbumin IgA monoclonal antibody. This antibody bound 
preferentially to metabolically active members of the 
Bacteriodales via glycan-lipopolysaccharide (LPS) interac-
tions. Binding of this highly glycosylated, antigen-inde-
pendent antibody altered microbial expression of 
polysaccharide utilization loci (PUL) genes, particularly 
in mucosal-associated bacteria, and not bacteria present 
in the colonic content [91]. Highly expressed PUL genes 
included components of the starch utilization system, 
which the authors propose act as symbiotic factors ena-
bling bacterial presence in the mucous environment, and 
have provisionally named them as mucous-associated 
functional factors (MAFFs) [91]. A complex interaction 
between B. thetaiotaomicron in the mucous, expression 
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of MAFFs and presence of other symbiotic partners was 
required for the full effect of MAFFs. IgA binding-induced 
expression of MAFFs drove the expansion of butyrate-
producing Clostridiales and promoted colonic homoeostasis 
protecting in a model of colitis [91]. IgA has been known 
for some time to be important in regulating gut microbial 
composition [63], but this study is the first to describe 
such complex interplay between a host factor (IgA), micro-
bial selection in a given niche and interphylum microbial 
interaction, resulting in metabolites that benefit the host.
IgA has also been suggested to limit microbial metabolite 
penetration, thus impacting on the host response to micro-
bial metabolites [92]. Uchimura et al. [92] colonized 
germ-free mice with a replication-deficient Escherichia coli 
which had been grown in 12C-labelled medium, enabling 
them to trace metabolites that originated from the bac-
teria  within tissues and urine. Because of the transient 
colonization, they could compare between mice that had 
received no prior colonization and those that had and 
therefore had IgA induction. They found that IgA pro-
moted the clearance of metabolites from the host tissues 
by accelerating microbial clearance [92]. While this study 
was able to show that IgA affects the distribution of 
metabolites in this setting, which would be in agreement 
with other studies showing the importance of IgA in 
selecting bacterial species and affecting the time bacteria 
reside in the gut [85,86,89], whether the same kind of 
effects would be applicable in the more complex setting 
of a colonized gut is uncertain. For example, several stud-
ies show that IgA can increase the dwell time of certain 
bacteria, which can have follow-on effects on the wider 
microbial composition and metabolite availability [90,91]. 
Nevertheless, all these studies demonstrate the importance 
of IgA in the regulation of the microbiota composition, 
which thereby affects metabolic activity of the microbiome 
and metabolites released into the host system.
Metabolic interplay between host, microbiota and 
pathogens
Some of the studies discussed above describe examples 
of interphylum co-operation via metabolites. This section 
expands on that theme and will highlight some examples 
of co-infections relying on metabolic subversion, or uti-
lization of certain metabolites, to aid infection or promote 
host responses.
A type 2 innate immune circuit between the microbiota, 
intestinal tuft cells and group 2 innate lymphoid cells 
(ILC2s) has been described by several groups [93–95]. 
Intestinal tuft cells are a population of chemosensory cells 
that can be found in the airways, trachea and intestinal 
tract [96]. In the small intestine they have been described 
to produce interleukin (IL)-25 upon helminth infection. 
This initiates IL-13 production by ILC2s, which feeds back 
on epithelial progenitor cells and biases their differentia-
tion into goblet and tuft cells, thus promoting a positive 
feed-forward loop that promotes worm clearance [93–95]. 
Recent reports found that the tuft cell–ILC2 circuit could 
be induced by microbial-derived succinate binding to 
G-protein coupled receptor 91 (GPR91, also known as 
succinate receptor 1, SUCNR1) [97–100]. SUCNR1 is 
specifically expressed on small intestinal tuft cells, and 
ligation with succinate induces a downstream chemosens-
ing pathway involving α-gustducin (Gnat3) and Trpm5. 
Supplementing succinate in the drinking water was suf-
ficient to activate SUCNR1 and induce the IL-25–ILC2–
IL-13-driven expansion of goblet and tuft cells. Succinate 
produced by the protist Tritrichomonas also drove a type-2 
response through SUCNR1 signalling. In the context of 
helminth infection, however, SUCNR1 signalling appeared 
redundant or absent, although downstream activation of 
Trpm5 and IL-25 occurs [99,100], although one of these 
studies showed that activation of this type 2 circuit by 
Tritrichomonas-derived succinate protected from subse-
quent infection with helminths [97]. This would suggest 
that the expansion of goblet and tuft cells is important 
for limiting infection with helminths. Even though hel-
minths may be able to produce succinate during infection, 
helminth-derived succinate does not induce SUCNR1 
signalling. This may be due to suppression of succinate 
production, use of alternative pathways or perhaps locali-
zation of succinate production.
Several studies have shown the important effects of 
aryl hydrocarbon receptor (AHR) ligands on the gut epi-
thelium, maintaining the stem cell niche, barrier function 
and protection from tumorigenesis and infection [101], 
as well as important effects on immune cells and periph-
eral inflammatory responses [102,103]. AHR ligands also 
regulate mucosal immunity through induction of IL-22, 
a cytokine important for epithelial restitution, induction 
of anti-microbial peptides and regulation of inflammation 
[104]. Zelante et al. [105] found that tryptophan metabo-
lism by stomach-resident commensal Lactobacillus reuteri 
resulted in indole-3-aldehyde production (IAld), which 
they showed activated AHR signalling in NKp46+  cells 
(and possibly also other cell types) which increased IL-22 
production by stomach epithelia. This, they demonstrated, 
was important for resistance against Candida albicans 
infection [105]. Increasing tryptophan supply by dietary 
supplementation, or deletion of host indolamine 2,3-dioxy-
genase 1 (IDO1), increased levels of the tryptophan 
metabolite IAld specifically (due to enzymatic pathways 
present in L. reuteri), which mediated these effects [105].
Caspase recruitment domain-containing protein 9 
(CARD9) is a signalling adaptor protein involved in inte-
grating signals from a range of innate receptors, including 
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C-type lectin and nucleotide-binding oligomerization 
domain-like (NOD) receptors, and is thus involved in 
bacterial, viral and fungal immune responses [106]. CARD9 
deficiency was found to affect gut microbial composition 
and had a resultant effect on tryptophan metabolism [107]. 
Reductions in certain bacterial populations, including L. 
reuteri and Allobaculum sp., was associated with dimin-
ished indole-3-acetic acid (IAA) production in the colon 
[107]. Accordingly, faeces from CARD9–/– mice had 
reduced ability to activate an AHR reporter, indicating 
the potential of microbial-derived IAA to signal through 
AHR. CARD9–/– mice were more susceptible to colitis, 
in concordance with CARD9 being a risk allele for IBD 
in humans. Adding an AHR agonist rescued IL-22 and 
adenosine monophosphate (AMP) production and pro-
tected from colitis in CARD9–/–, again showing the impor-
tance of AHR ligands in promoting IL-22 production 
and epithelial barrier function. Furthermore, IL-22 itself 
alters microbial composition, particularly reducing 
Lactobacillus sp. [107,108], probably through the produc-
tion of AMPs, and thereby affects tryptophan metabolism, 
forming a cyclical relationship between microbial trypto-
phan metabolism, AHR agonism, IL-22 production and 
modulation of the intestinal epithelium [107].
IL-22 production is increased upon enteric infection 
and is protective against some pathogens, such as 
Citrobacter rodentium, and colitis, as discussed above and 
elsewhere [107,109–111]. However, IL-22 can promote 
colonization by other pathogens such as S. typhimurium 
by controlling growth of its niche competitor E. coli [112]. 
In a study by Grizotte-Lake et al. [113] they found that 
commensal microbes suppress small intestinal epithelial 
expression of Rdh7, an enzyme required for retinoic acid 
(RA) production, resulting in reduced RA in SPF mice 
compared to germ-free mice. This effect was due to spore-
forming Clostridia sp. The reduction in RA in SPF mice 
resulted in diminished IL-22 production by ILC3s and 
other T cell populations. To understand the effects of 
Rdh7, they used Rdh7–/– mice and could recapitulate the 
reduction in RA and IL-22. This resulted in decreased 
production of AMPs by the small intestinal epithelium 
which led to alterations in the gut microbiota, and pro-
moted host resistance to S. typhimurium infection (there 
was no effect on C. rodentium infection). Along with the 
studies described above [107,108], this suggests that a 
degree of tonic regulation of IL-22 mediated by the gut 
microbiota is important for modulating gut microbial 
composition and also susceptibility to intestinal pathogens. 
This highlights how these networks need to be finely tuned 
in order to promote homoeostatic interactions between 
host and commensals while limiting pathogens.
Pathogens can alter the gastrointestinal environment 
to enable them to thrive. Salmonella spp. virulence 
factors induce inflammation in the mucosa characterized 
by neutrophil recruitment. Neutrophils, and the inflam-
mation induced, release a large amount of electron 
acceptors, such as tetrathionate and nitrate, which fuel 
Salmonella metabolism, allowing their expansion while 
altering the gut microbial composition, including the 
depletion of Clostridia spp. [114,115]. This causes a 
reduction in butyrate which alters metabolic activity of 
enterocytes which usually rely on butyrate, as discussed 
above, and thus leads to increased oxygen availability, 
further supporting Salmonella growth [7]. Changes in 
enterocyte metabolism were found to generate lactate 
which, along with the increase in oxygen, Salmonella 
could use as an energy source with oxygen as the final 
electron acceptor [70]. Furthermore, it was recently 
reported that Salmonella can utilize microbiota-derived 
succinate and host-derived electron acceptors to enable 
a complete oxidative tricarboxylic acid (TCA) cycle [116]. 
Thus, pathogens such as Salmonella spp. can actively 
induce dysbiosis, or dysbiosis through other causes can 
support the growth of Salmonella.
More complex interactions between host and microbial 
species can occur in co-infection settings. Chronic hel-
minth infections are associated with increased occurrence 
of co-infections with a range of bacterial and viral patho-
gens [117–120]. Induction of type 2 (Th2) immune 
responses and Tregs is thought to play a major role in 
limiting protective Th1 and Th17 responses required to 
clear bacterial and viral pathogens [118–121]. Helminth 
infections can alter the microbial composition and have 
been shown to increase SCFA production, which can 
alleviate allergic airway inflammation and colitis [122,123]. 
Using a co-infection model, Reynolds et al. [124] found 
that helminth infection (Heligmosomoides polygyrus) 
altered the metabolome of small intestinal epithelial cells, 
which has a resultant effect on Salmonella expression of 
invasion genes within the Salmonella pathogenicity island-1 
(SPI-1). Metabolites extracted from naive small intestinal 
epithelial cells could supress SPI-1 expression and reduce 
invasion of Salmonella in an in-vitro invasion assay, whereas 
helminth-infected epithelial metabolites could not, and 
thus increased Salmonella invasion was observed if mice 
were already infected with helminths [124]. This study 
did not identify individual metabolites that exert this effect, 
so whether individual or multiple metabolites are respon-
sible is yet to be determined. Given that helminths, or 
helminth-derived products, are of interest as therapeutic 
interventions for allergic airway and inflammatory bowel 
disease, it is important to understand possible negative 
impacts they may have in promoting co-infections [124].
Altogether, these studies highlight the complex interac-
tions between host and microbes, as well as intermicrobial 
interactions, many of which are mediated by, or involve 
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subversion of, metabolic pathways and metabolites. 
Epithelial metabolism and physiological hypoxia are central 
to the host–microbe relationship. As colonocytes are dif-
ferentiated at the top of the crypts they express PPARγ, 
which switches on β-oxidation of butyrate and oxidative 
phosphorylation which consumes oxygen. By the induc-
tion of physiological hypoxia, HIF becomes stabilized and 
then induces transcription of essential genes required for 
epithelial barrier function, such as tight junction proteins, 
anti-microbial peptides and mucous production. The 
hypoxic environment created then favours obligate anaer-
obes which act in a mutualistic relationship, providing 
the main energy source, butyrate, for the colonocytes by 
fermentation of dietary fibre (Fig. 1). This establishes 
obligate anaerobes as the dominant bacteria within the 
colon, and further metabolites derived from the microbiota, 
such as acetate, lactate, AHR ligands, indole-derived mol-
ecules, etc. are now appreciated to exert a broad range 
of effects on immune and host function, as well as feeding 
back to select the  microbiome further via IgA or anti-
microbial peptides. These processes, from epithelial metab-
olism to maintenance of obligate anaerobes, are disrupted 
during infections, even purposefully, favouring facultative 
anaerobes or aerobes, which can have deleterious effects 
on the host.
Future considerations in this area would be to under-
stand more clearly the development of epithelial metabolic 
pathways, understand any differences between small intes-
tine and the colon and how fluctuations in oxygen could 
be affecting the microbiome and therefore host function. 
As discussed above, constant feeding leading to increased 
blood flow and oxygenation in the intestinal tract could 
be deleterious and one way by which a western lifestyle 
may be causing dysbiosis and increased susceptibility to 
inflammatory diseases. It is also of interest that chronic 
bowel inflammation, such as in Crohn’s disease or ulcera-
tive colitis, causes increased angiogenesis in the intestinal 
tract, and thus increased oxygen availability might be one 
reason for poor treatment outcomes in many patients, 
where dysbiosis and ongoing inflammation are concomitant 
factors [125]. In addition to increased angiogenesis, intes-
tinal inflammation is also associated with bleeding in to 
the gut lumen, which also delivers increased haem-bound 
oxygen. As such, targeting oxygen has been proposed as 
a treatment option for inflammatory bowel diseases [8].
Some obligate anaerobic commensals cope with oxygen 
by employing mechanisms such as extracellular electron 
shuttles, which add electrons to oxygen. This relies upon 
flavins and thiols being present in the gut; however, dur-
ing inflammation thiols become depleted [8,126]. Faecal 
microbiota transplant has been employed successfully for 
C. difficile-infected patients, and is entering use for further 
conditions from inflammatory bowel disease to asthma 
and cancer treatment. However, defining ‘good’ faecal 
donors is a challenge, and presence of microbial species 
that are good colonizers and have traits such as being 
able to utilize and deplete oxygen may be an important 
consideration.
In summary, metabolism and metabolites are the basis 
of host–microbe interactions. Further understanding of 
these metabolic interactions will be important for devel-
oping treatment strategies for inflammatory bowel diseases 
as well as the wide range of other diseases associated 
with dysbiosis.
Acknowledgements
K. M. M. is a Birmingham Fellow and is supported by 
the Wellcome Trust [214087/Z/18/Z] and Cancer Research 
UK [C61638/A27112].
Disclosures
The author declares no conflict of interest.
References
 1 O’Hara AM, Shanahan F. The gut flora as a forgotten organ. 
EMBO Rep 2006; 7:688–93.
 2 Engel P, Moran NA. The gut microbiota of insects – diversity 
in structure and function. FEMS Microbiol Rev 2013; 
37:699–735.
 3 Maslowski KM, MacKay CR. Diet, gut microbiota and immune 
responses. Nat Immunol 2011; 12:5–9.
 4 Li X, Watanabe K, Gut Kimura I. Microbiota dysbiosis drives 
and implies novel therapeutic strategies for diabetes mellitus 
and related metabolic diseases. Front Immunol Frontiers Media 
SA 2017; 8:1882.
 5 Scriven M, Dinan TG, Cryan JF, Wall M. Neuropsychiatric 
disorders: influence of gut microbe to brain signalling. Diseases 
(Basel) 2018; 6:78.
 6 Valles-Colomer M, Falony G, Darzi Y et al. The neuroactive 
potential of the human gut microbiota in quality of life and 
depression. Nat Microbiol 2019; 4:623–32.
 7 Litvak Y, Byndloss MX, Bäumler AJ. Colonocyte metabolism 
shapes the gut microbiota. Science 2018; 362:eaat9076.
 8 Rigottier-Gois L. Dysbiosis in inflammatory bowel diseases: 
the oxygen hypothesis microbe–microbe and microbe–host 
interactions. ISME J 2013; 7:1256–61.
 9 Vogelzang A, Guerrini MM, Minato N, Fagarasan S. 
Microbiota  –  an amplifier of autoimmunity. Curr Opin 
Immunol 2018; 55:15–21.
 10 Gordon HA, Pesti L. The gnotobiotic animal as a tool in the 
study of host microbial relationships. Bacteriol Rev 1971; 
35:390.
 11 Wostmann BS. The germfree animal in nutritional studies. 
Ann RevNutr 1981; 1:257–279.
Metabolism at the centre of the host–microbe relationship
© 2019 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society 
for Immunology, Clinical and Experimental Immunology, 00: 00–00
9
 12 Backhed F, Ding H, Wang T et al. The gut microbiota as 
an environmental factor that regulates fat storage. Proc Natl 
Acad Sci USA 2004; 101:15718–23.
 13 Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-induced 
obesity is linked to marked but reversible alterations in the 
mouse distal gut microbiome. Cell Host Microbe 2008; 
3:213–23.
 14 Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon 
JI. The effect of diet on the human gut microbiome: a 
metagenomic analysis in humanized gnotobiotic mice. Sci 
Transl Med 2009; 1:6ra14.
 15 Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis 
ER, Gordon JI. An obesity-associated gut microbiome with 
increased capacity for energy harvest. Nature 2006; 
444:1027–31.
 16 Turnbaugh PJ, Hamady M, Yatsunenko T et al. A core gut 
microbiome in obese and lean twins. Nature 2009; 
457:480–4.
 17 Donohoe DR, Garge N, Zhang X et al. The microbiome and 
butyrate regulate energy metabolism and autophagy in the 
mammalian colon. Cell Metab 2011; 13:517–26.
 18 Roediger WE. Utilization of nutrients by isolated epithelial 
cells of the rat colon. Gastroenterology 1982; 83:424–9.
 19 Salleh M, Ardawi M, Newsholme EA. Fuel utilization in 
colonocytes of the rat. Biochem J 1985; 231:713–19.
 20 Roediger WE. Role of anaerobic bacteria in the metabolic 
welfare of the colonic mucosa in man. Gut 1980; 
21:793–98.
 21 Kelly CJ, Zheng L, Campbell EL et al. Crosstalk between 
microbiota-derived short-chain fatty acids and intestinal 
epithelial HIF augments tissue barrier function. Cell Host 
Microbe 2015; 17:662–71.
 22 Schaedler RW, Dubos R, Costello R. The development of the 
bacterial flora in the gastrointestinal tract of mice. J Exp Med 
1965; 122:59–66.
 23 McAllisterv JS, Savage DC. Microbial colonization of the 
intestinal epithelium in suckling mice. Infect Immun 1973; 
7:666–72.
 24 Gillilland MG, Erb-Downward JR, Bassis CM et al. Ecological 
succession of bacterial communities during conventionalization 
of germ-free mice. Appl Environ Microbiol 2012; 
78:2359–66.
 25 Savage DC. Factors involved in colonization of the gut epithelial 
surface. Am J Clin Nutr 1978; 31:S131–5.
 26 Furuta GT, Turner JR, Taylor CT et al. Hypoxia-inducible 
factor 1–dependent induction of intestinal trefoil factor protects 
barrier function during Hypoxia. J Exp Med 2001; 
193:1027–34.
 27 Byndloss MX, Olsan EE, Rivera-Chávez F et al. Microbiota-
activated PPAR-γ signaling inhibits dysbiotic 
Enterobacteriaceae expansion. Science 2017; 357:570–5.
 28 Litvak Y, Mon KKZ, Nguyen H et al. Commensal 
enterobacteriaceae protect against Salmonella colonization 
through oxygen competition. Cell Host Microbe 2019; 25:128–
39.e5.
 29 Lefebvre M, Paulweber B, Fajas L et al. Peroxisome proliferator-
activated receptor gamma is induced during differentiation 
of colon epithelium cells. J Endocrinol 1999; 162:331–40.
 30 Espey MG. Role of oxygen gradients in shaping redox 
relationships between the human intestine and its microbiota. 
Free Rad Biol Med 2013; 55:130–40.
 31 Albenberg L, Esipova TV, Judge CP et al. Correlation between 
intraluminal oxygen gradient and radial partitioning of 
intestinal microbiota. Gastroenterology 2014;147:1055–63.e8.
 32 Zheng L, Kelly CJ, Colgan SP. Physiologic hypoxia and oxygen 
homeostasis in the healthy intestine. A review in the theme: 
cellular responses to hypoxia. Am J Physiol Cell Physiol 2015; 
309:C350–60.
 33 Wächtershäuser A, Loitsch SM, Stein J. PPAR-γ Is selectively 
upregulated in caco-2 cells by butyrate. Biochem Biophys Res 
Commun 2000; 272:380–5.
 34 Glover LE, Colgan SP. Epithelial barrier regulation by hypoxia-
inducible factor. Ann Am Thorac Soc 2017; 14(Suppl 3);S233–6.
 35 Zheng L, Kelly CJ, Colgan SP. Physiologic hypoxia and oxygen 
homeostasis in the healthy intestine. A review in the theme: 
cellular responses to hypoxia. Am J Physiol Cell Physiol 2015; 
309:C350–60.
 36 Dashwood RH, Myzak MC, Ho E. Dietary HDAC inhibitors: 
time to rethink weak ligands in cancer chemoprevention? 
Carcinogenesis 2006; 27:344–9.
 37 Wells JM, Mercenier A. Mucosal delivery of therapeutic and 
prophylactic molecules using lactic acid bacteria. Nat Rev 
Microbiol 2008; 6:349–62.
 38 Gill HS, Rutherfurd KJ, Prasad J, Gopal PK. Enhancement 
of natural and acquired immunity by Lactobacillus rhamnosus 
(HN001), Lactobacillus acidophilus (HN017) and 
Bifidobacterium lactis (HN019). Br J Nutr 2000; 83:167–76.
 39 Perdigon G, Alvarez S, Rachid M, Agüero G, Gobbato N. 
Immune system stimulation by probiotics. J Dairy Sci 1995; 
78:1597–606.
 40 Watanabe T, Nishio H, Tanigawa T et al. Probiotic Lactobacillus 
casei strain Shirota prevents indomethacin-induced small 
intestinal injury: involvement of lactic acid. Am J Physiol 
Liver Physiol 2009; 297:G506–13.
 41 Lee Y-S, Kim T-Y, Kim Y et al. Lactate accelerates intestinal 
stem-cell-mediated epithelial development in brief. Cell Host 
Microbe 2018; 24:833–46.
 42 Cai T-Q, Ren N, Jin L et al. Role of GPR81 in lactate-
mediated reduction of adipose lipolysis. Biochem Biophys Res 
Commun 2008; 377:987–91.
 43 Ge H, Weiszmann J, Reagan JD et al. Elucidation of signaling 
and functional activities of an orphan GPCR, GPR81. J Lipid 
Res 2008; 49:797–803.
 44 Liu C, Wu J, Zhu J et al. Lactate inhibits lipolysis in fat 
cells through activation of an orphan g-protein-coupled 
receptor, GPR81. J Biol Chem 2009; 284:2811–22.
K. M. Maslowski
© 2019 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for 
Immunology, Clinical and Experimental Immunology, 00: 00–00
10
 45 Sato T, van Es JH, Snippert HJ et al. Paneth cells constitute 
the niche for Lgr5 stem cells in intestinal crypts. Nature 2011; 
469:415–18.
 46 Gregorieff A, Pinto D, Begthel H, Destrée O, Kielman M, 
Clevers H. Expression pattern of Wnt signaling components 
in the adult intestine. Gastroenterology 2005; 129:626–38.
 47 Valenta T, Degirmenci B, Moor AE et al. Wnt ligands secreted 
by subepithelial mesenchymal cells are essential for the sur-
vival of intestinal stem cells and gut homeostasis. Cell Rep 
2016; 15:911–18.
 48 Mardinoglu A, Shoaie S, Bergentall M et al. The gut microbiota 
modulates host amino acid and glutathione metabolism in 
mice. Mol Syst Biol 2015; 11:834–34.
 49 Lin R, Liu W, Piao M, Zhu H. A review of the relationship 
between the gut microbiota and amino acid metabolism. Amino 
Acids 2017; 49:2083–90.
 50 Neis EPJG, Dejong CHC, Rensen SS. The role of microbial 
amino acid metabolism in host metabolism. Nutrients 2015; 
7:2930–46.
 51 Palego L, Betti L, Rossi A, Giannaccini G. Tryptophan 
biochemistry: structural, nutritional, metabolic, and medical 
aspects in humans. J Amino Acids 2016; 2016:8952520.
 52 Dodd D, Spitzer MH, Van Treuren W et al. A gut bacterial 
pathway metabolizes aromatic amino acids into nine circulating 
metabolites. Nature 2017; 551:648–52.
 53 Wikoff WR, Anfora AT, Liu J et al. Metabolomics analysis 
reveals large effects of gut microflora on mammalian blood 
metabolites. Proc Natl Acad Sci USA 2009; 106:3698–703.
 54 Roager HM, Licht TR. Microbial tryptophan catabolites in 
health and disease. Nat Commun 2018; 9:3294.
 55 Venkatesh M, Mukherjee S, Wang H et al. Article symbiotic 
bacterial metabolites regulate gastrointestinal barrier function 
via the xenobiotic sensor PXR and Toll-like receptor 4. 
Immunity 2014; 41:296–310.
 56 Bhattarai Y, Williams BB, Battaglioli EJ et al. Microbiota-
produced tryptamine activates an epithelial g-protein-coupled 
receptor to increase colonic secretion. Cell Host Microbe 2018; 
23:775–85.e5.
 57 Sung J, Kim S, Cabatbat JJT et al. Global metabolic interaction 
network of the human gut microbiota for context-specific 
community-scale analysis. Nat Commun 2017; 8:15393.
 58 Rojo D, Hevia A, Bargiela R et al. Ranking the impact of 
human health disorders on gut metabolism: systemic lupus 
erythematosus and obesity as study cases. Sci Rep 2015; 5:8310.
 59 De Vadder F, Kovatcheva-Datchary P, Zitoun C, Duchampt 
A, Bäckhed F, Mithieux G. Microbiota-produced succinate 
improves glucose homeostasis via intestinal gluconeogenesis. 
Cell Metab 2016; 24:151–7.
 60 Kranich J, Maslowski KM, Mackay CR. Commensal flora and 
the regulation of inflammatory and autoimmune responses. 
Semin Immunol 2011; 23:139–45.
 61 Rodríguez-Carrio J, López P, Sánchez B et al. Intestinal dysbiosis 
is associated with altered short-chain fatty acids and 
serum-free fatty acids in systemic lupus erythematosus. Front 
Immunol 2017; 8:23.
 62 Treem WR, Ahsan N, Shoup M, Hyams JS. Fecal short-chain 
fatty acids in children with inflammatory bowel disease. J 
Pediatr Gastroenterol Nutr 1994; 18:159–64.
 63 Brown AJ, Goldsworthy SM, Barnes AA et al. The Orphan 
G protein-coupled receptors GPR41 and GPR43 are activated 
by propionate and other short chain carboxylic acids. J Biol 
Chem 2003; 278:11312–9.
 64 Le Poul E, Loison C, Struyf S et al. Functional characterization 
of human receptors for short chain fatty acids and their role 
in polymorphonuclear cell activation. J Biol Chem 2003; 
278:25481–9.
 65 Maslowski KM, Vieira AT, Ng A et al. Regulation of 
inflammatory responses by gut microbiota and chemoattractant 
receptor GPR43. Nature 2009; 461:1282–6.
 66 Tan J, McKenzie C, Vuillermin PJ et al. Dietary fiber and bac-
terial SCFA enhance oral tolerance and protect against food allergy 
through diverse cellular pathways. Cell Rep 2016; 15:2809–24.
 67 Macia L, Tan J, Vieira AT et al. Metabolite-sensing receptors 
GPR43 and GPR109A facilitate dietary fibre-induced gut 
homeostasis through regulation of the inflammasome. Nat 
Commun 2015; 6:6734.
 68 Vieira AT, Macia L, Galvao I et al. A role for gut microbiota 
and the metabolite-sensing receptor GPR43 in a murine model 
of gout. Arthritis Rheumatol 2015; 67:1646–56.
 69 Trompette A, Gollwitzer ES, Yadava K et al. Gut microbiota 
metabolism of dietary fiber influences allergic airway disease 
and hematopoiesis. Nat Med 2014; 20:159–66.
 70 Gillis CC, Hughes ER, Spiga L et al. Change in host metabolism 
generates lactate to support salmonella growth. Cell Host 
Microbe 2018; 23:54–64.e6.
 71 Lynn MA, Tumes DJ, Choo JM et al. Antibiotic-driven dysbiosis 
leads to dysregulated vaccine immune responses in mice. Cell 
Host Microbe 2018; 23: 653–60.e5.
 72 Lazar V, Ditu L-M, Pircalabioru GG et al. Aspects of gut 
microbiota and immune system interactions in infectious 
diseases, immunopathology, and cancer. Front Immunol 2018; 
9:1830.
 73 Romick-Rosendale LE, Haslam DB, Lane A et al. Antibiotic 
exposure and reduced short chain fatty acid production after 
hematopoietic stem cell transplant. Biol Blood Marrow 
Transplant 2018; 24:2418–24.
 74 Clausen MR, Bonnén H, Tvede M, Brøbech Mortensen P. 
Colonic fermentation to short-chain fatty acids is decreased 
in antibiotic-associated diarrhea. Gastroenterology 1991; 
101:1497–504.
 75 Scott NA, Andrusaite A, Andersen P et al. Antibiotics induce 
sustained dysregulation of intestinal T cell immunity by 
perturbing macrophage homeostasis. Sci Transl Med 
2018;10:eaao4755.
 76 Wu W, Sun M, Chen F et al. Microbiota metabolite short-
chain fatty acid acetate promotes intestinal IgA response to 
Metabolism at the centre of the host–microbe relationship
© 2019 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society 
for Immunology, Clinical and Experimental Immunology, 00: 00–00
11
microbiota which is mediated by GPR43. Mucosal Immunol 
2017; 10:946–56.
 77 Furusawa Y, Obata Y, Fukuda S et al. Commensal microbe-
derived butyrate induces the differentiation of colonic 
regulatory T cells. Nature 2013; 504:446–50.
 78 Smith PM, Howitt MR, Panikov N et al. The microbial 
metabolites, short-chain fatty acids, regulate colonic Treg cell 
homeostasis. Science 2013; 341:569–73.
 79 Tyagi AM, Yu M, Darby TM et al. The microbial metabolite 
butyrate stimulates bone formation via T regulatory cell-
mediated regulation of WNT10B expression. Immunity 2018; 
49:1116–31.e7.
 80 Thorburn AN, McKenzie CI, Shen S et al. Evidence that 
asthma is a developmental origin disease influenced by mater-
nal diet and bacterial metabolites. Nat Commun 2015; 
6:7320.
 81 Nakajima A, Kaga N, Nakanishi Y et al. Maternal high fiber 
diet during pregnancy and lactation influences regulatory T 
cell differentiation in offspring in mice. J Immunol 2017; 
199:3516–24.
 82 Nakajima A, Negishi N, Tsurui H et al. Commensal bacteria 
regulate thymic Aire expression. PLOS ONE 2014; 9:e105904.
 83 Morita N, Umemoto E, Fujita S et al. GPR31-dependent 
dendrite protrusion of intestinal CX3CR83 + cells by bacterial 
metabolites. Nature 2019; 566:110–14.
 84 Ranganathan P, Shanmugam A, Swafford D et al. GPR81, a 
cell-surface receptor for lactate, regulates intestinal homeostasis 
and protects mice from experimental colitis. J Immunol 2018; 
200:1781–9.
 85 Fagarasan S, Muramatsu M, Suzuki K, Nagaoka H, Hiai H, 
Honjo T. Critical roles of activation-induced cytidine deaminase 
in the homeostasis of gut flora. Science 2002; 298:1424–7.
 86 Fadlallah J, El Kafsi H, Sterlin D et al. Microbial ecology 
perturbation in human IgA deficiency. Sci Transl Med 2018; 
10:eaan1217.
 87 Wang N, Shen N, Vyse TJ et al. Selective IgA deficiency in 
autoimmune diseases. Mol Med 2011; 17:1383–96.
 88 Mantis NJ, Rol N, Corthésy B. Secretory IgA’s complex roles 
in immunity and mucosal homeostasis in the gut. Mucosal 
Immunol 2011; 4:603–11.
 89 Moor K, Diard M, Sellin ME et al. High-avidity IgA protects 
the intestine by enchaining growing bacteria. Nature 2017; 
544:498–502.
 90 Donaldson GP, Ladinsky MS, Yu KB et al. Microbiota utilize 
immunoglobulin A for mucosal colonization. Science 2018; 
360:795–800.
 91 Nakajima A, Vogelzang A, Maruya M et al. IgA regulates 
the composition and metabolic function of gut microbiota 
by promoting symbiosis between bacteria. J Exp Med 2018; 
215:2019–34.
 92 Uchimura Y, Fuhrer T, Li H et al. Antibodies set boundaries 
limiting microbial metabolite penetration and the resultant 
mammalian host response. Immunity 2018; 49:545–59.e5.
 93 Gerbe F, Sidot E, Smyth DJ et al. Intestinal epithelial tuft 
cells initiate type 2 mucosal immunity to helminth parasites. 
Nature 2016; 529:226–30.
 94 Howitt MR, Lavoie S, Michaud M et al. Tuft cells, taste-
chemosensory cells, orchestrate parasite type 2 immunity in 
the gut. Science 2016; 351:1329–33.
 95 von Moltke J, Ji M, Liang H-E, Locksley RM. Tuft-cell-derived 
IL-25 regulates an intestinal ILC2–epithelial response circuit. 
Nature 2016; 529:221–5.
 96 Sato A. Tuft cells. Anat Sci Int 2007; 82:187–99.
 97 Schneider C, O’Leary CE, von Moltke J et al. Metabolite-
triggered tuft cell-ILC2 circuit drives small intestinal 
remodeling. Cell 2018; 174:271–84.e14.
 98 Hayakawa Y, Wang TC. The tuft cell-ILC2 circuit integrates 
intestinal defense and homeostasis. Cell 2018; 174:251–3.
 99 Nadjsombati MS, McGinty JW, Lyons-Cohen MR et al. 
Detection of succinate by intestinal tuft cells triggers a type 
2 innate immune circuit. Immunity 2018; 49:33–41.e7.
 100 Lei W, Ren W, Ohmoto M et al. Activation of intestinal tuft 
cell-expressed Sucnr1 triggers type 2 immunity in the mouse 
small intestine. Proc Natl Acad Sci USA 2018; 115:5552–7.
 101 Metidji A, Omenetti S, Crotta S et al. The environmental 
sensor AHR protects from inflammatory damage by 
maintaining intestinal stem cell homeostasis and barrier 
integrity. Immunity 2018; 49:353–62.e5.
 102 Rothhammer V, Mascanfroni ID, Bunse L et al. Type I 
interferons and microbial metabolites of tryptophan modulate 
astrocyte activity and central nervous system inflammation 
via the aryl hydrocarbon receptor. Nat Med 2016; 
22:586–97.
 103 Gutiérrez-Vázquez C, Quintana FJ. Regulation of the immune 
response by the aryl hydrocarbon receptor. Immunity 2018; 
48:19–33.
 104 Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation 
of immunity, inflammation and tissue homeostasis at barrier 
surfaces by IL-22. Nat Immunol 2011; 12:383–90.
 105 Zelante T, Iannitti RG, Cunha C et al. Article tryptophan 
catabolites from microbiota engage aryl hydrocarbon receptor 
and balance mucosal reactivity via interleukin-22. Immunity 
2013; 39:372–85.
 106 Drummond RA, Franco LM, Lionakis MS. Human CARD9: 
A Critical Molecule of Fungal Immune Surveillance. Front 
Immunol 2018; 9:1836.
 107 Lamas B, Richard ML, Leducq V et al. CARD9 impacts colitis 
by altering gut microbiota metabolism of tryptophan into 
aryl hydrocarbon receptor ligands. Nat Med 2016; 
22:598–605.
 108 Zenewicz LA, Yin X, Wang G et al. IL-22 deficiency alters 
colonic microbiota to be transmissible and colitogenic. J 
Immunol 2013; 190:5306–12.
 109 Zheng Y, Valdez PA, Danilenko DM et al. Interleukin-22 
mediates early host defense against attaching and effacing 
bacterial pathogens. Nat Med 2008; 14:282–289.
K. M. Maslowski
© 2019 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for 
Immunology, Clinical and Experimental Immunology, 00: 00–00
12
 110 Mizoguchi A. Healing of intestinal inflammation by IL-22. 
Inflamm Bowel Dis 2012; 18:1777–84.
 111 Allam R, Maillard MH, Tardivel A et al. Epithelial NAIPs 
protect against colonic tumorigenesis. J Exp Med 2015; 
212:369–83.
 112 Behnsen J, Jellbauer S, Wong CP et al. The cytokine IL-22 
promotes pathogen colonization by suppressing related 
commensal bacteria. Immunity 2014; 40:262–73.
 113 Grizotte-Lake M, Zhong G, Duncan K et al. Commensals 
suppress intestinal epithelial cell retinoic acid synthesis to 
regulate interleukin-22 activity and prevent microbial dysbiosis. 
Immunity 2018; 49:1103–15.e6.
 114 Stecher B, Robbiani R, Walker AW et al. Salmonella enterica 
serovar Typhimurium exploits inflammation to compete with 
the intestinal microbiota. PLOS Biol 2007; 5:e244.
 115 Sekirov I, Gill N, Jogova M et al. Salmonella SPI-1-mediated 
neutrophil recruitment during enteric colitis is associated with 
reduction and alteration in intestinal microbiota. Gut Microbes 
2010; 1:30–41.
 116 Spiga L, Winter MG, Furtado de Carvalho T et al. Oxidative 
central metabolism enables salmonella to utilize microbiota-
derived succinate. Cell Host Microbe 2017; 22:291–301.e6.
 117 Su L, Su C, Qi Y et al. Coinfection with an intestinal helminth 
impairs host innate immunity against Salmonella enterica 
serovar Typhimurium and exacerbates intestinal inflammation 
in mice. Infect Immun 2014; 82:3855–66.
 118 Chen C-C, Louie S, McCormick B, Walker WA, Shi HN. 
Concurrent infection with an intestinal helminth parasite 
impairs host resistance to enteric Citrobacter rodentium and 
enhances Citrobacter-induced colitis in mice. Infect Immun 
2005; 73:5468–81.
 119 Reese TA, Wakeman BS, Choi HS et al. Helminth infection 
reactivates latent γ-herpesvirus via cytokine competition at a 
viral promoter. Science 2014; 345:573–7.
 120 Osborne LC, Monticelli LA, Nice TJ et al. Virus-helminth 
coinfection reveals a microbiota-independent mechanism of 
immunomodulation. Science 2014; 345:578–82.
 121 Hsieh Y-J, Fu C-L, Hsieh MH. Helminth-induced interleukin-4 
abrogates invariant natural killer T cell activation-associated 
clearance of bacterial infection. Infect Immun 2014; 
82:2087–97.
 122 Zaiss MM, Rapin A, Lebon L et al. The intestinal microbiota 
contributes to the ability of helminths to modulate allergic 
inflammation. Immunity 2015; 43:998–1010.
 123 Ramanan D, Bowcutt R, Lee SC et al. Helminth infection 
promotes colonization resistance via type 2 immunity. Science 
2016; 352:608–12.
 124 Reynolds LA, Redpath SA, Yurist-Doutsch S et al. Enteric 
helminths promote salmonella coinfection by altering the 
intestinal metabolome. J Infect Dis 2017; 215:1245–54.
 125 Binion D, Rafiee P. Is inflammatory bowel disease a vascular 
disease? Targeting angiogenesis improves chronic inflammation 
in inflammatory bowel disease. Gastroenterology 2009; 
136:400–3.
 126 Khan MT, Duncan SH, Stams AJM, van Dijl JM, Flint HJ, 
Harmsen HJM. The gut anaerobe Faecalibacterium prausnitzii 
uses an extracellular electron shuttle to grow at oxic-anoxic 
interphases. ISME J 2012; 6:1578–85.
